Related references
Note: Only part of the references are listed.Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
Mohamad Shebley et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA
Christian Wagner et al.
CLINICAL PHARMACOKINETICS (2016)
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine
Dolly A. Parasrampuria et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model
Junichi Takano et al.
DRUG METABOLISM AND DISPOSITION (2016)
Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development: A Pharmaceutical Industry Perspective
H. M. Jones et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration
Christian Wagner et al.
CLINICAL PHARMACOKINETICS (2015)
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
Jennifer E. Sager et al.
DRUG METABOLISM AND DISPOSITION (2015)
Edoxaban Transport via P-Glycoprotein Is a Key Factor for the Drug's Disposition
Tsuyoshi Mikkaichi et al.
DRUG METABOLISM AND DISPOSITION (2014)
Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
Jeanne Mendell et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2013)
The kinetics of invertin action
L. Michaelis et al.
FEBS LETTERS (2013)
Application of Permeability-Limited Physiologically-Based Pharmacokinetic Models: Part II - Prediction of P-Glycoprotein Mediated Drug-Drug Interactions with Digoxin
Sibylle Neuhoff et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential
Michael Gertz et al.
PHARMACEUTICAL RESEARCH (2013)
Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide
Manthena V. S. Varma et al.
PHARMACEUTICAL RESEARCH (2013)
Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach
Karen Rowland Yeo et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2013)
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects
Nobuko Matsushima et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
H. M. Jones et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans
Mohinder S. Bathala et al.
DRUG METABOLISM AND DISPOSITION (2012)
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Malcolm Rowland et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions
Eleanor J. Guest et al.
DRUG METABOLISM AND DISPOSITION (2011)
Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass
Arnaud Bruyere et al.
MOLECULAR PHARMACEUTICS (2010)
Drug-Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro-In Vivo Correlation Using Digoxin as a Probe Drug
K. S. Fenner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Challenges and opportunities with modelling and simulation in drug discovery and drug development
T. Lave et al.
XENOBIOTICA (2007)
Whole-body physiologically based pharmacokinetic models
Ivan Nestorov
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Prediction of in vivo drug clearance from in vitro data.: II:: Potential inter-ethnic differences
S. Inoue et al.
XENOBIOTICA (2006)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
M Shimizu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans
S Haddad et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A (2001)
Predicting the impact of physiological and biochemical processes on oral drug bioavailability
B Agoram et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
Share Paper
